DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/22/21

Shares of Deciphera Pharmaceuticals are (NASDAQ:DCPH) up 6% after the European Commission approved Qinlock (ripretinib) as a fourth-line treatment for gastrointestinal stromal tumors. A pivotal trial showed that the drug increased overall survival compared to best supportive care. It also mai...

Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...

– QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company de...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short selling biotechnology stocks is a dangerous game to play. However, Deciphera Pharmaceuticals (NASDAQ: DCPH ) has been a boon to the bears as DCPH stock is far below its peak price. Source: Iryna Imago / Shut...

After a setback in a late-stage cancer trial wiped off more than three-quarters of its market cap on Friday, Deciphera Pharmaceuticals (NASDAQ:DCPH) has added ~3.4% in the pre-market. The Phase 3 INTRIGUE designed to assess Qinlock as a potential treatment for a certain group of pat...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to fresh record highs Friday following a stronger than expected jobs report that showed 531,000 jobs added in October and a re...

Friday's standout performers were largely defined by their relationship to Pfizer. The drug maker announced blockbuster results from a clinical trial of its COVID pill, revealing an 89% reduction in risk for hospitalization or death. In response, travel stocks rallied, including substantial g...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Any time a stock moves down 75% over a given period of time, investors have reason to be concerned. When such a move happens in a given trading day, it’s time to ring the alarm bells. For investors in Deciphera Ph...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Deciphera Pharmaceuticals, Inc. Shares Fell 73% After its INTRIGUE Phase 3 Clinical Study Failed to Meet its Primary Endpoint” Deciphera Pharmaceuticals, I...

Shares of Deciphera Pharmaceuticals Inc ( NASDAQ: DCPH ) tanked 75% on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp decline wiped millions off its market cap that now stands at $565 million. Decipher...